Friday, May 16, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

GuruFocus News. 16/05/2025 
The U.S. FDA has granted IND clearance for SGT-212, intended for treating Friedreich's Ataxia, with first participant dosing anticipated in the second half of 2025.